- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 249/12 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 249/12
Total number of patents in this class: 632
10-year publication summary
|
36
|
40
|
46
|
53
|
39
|
46
|
25
|
22
|
39
|
13
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 20940 |
22 |
| Theravance Biopharma R&D IP, LLC | 456 |
22 |
| Synta Pharmaceuticals Corp. | 174 |
21 |
| Bayer Pharma AG | 1053 |
16 |
| Bayer AG | 3325 |
14 |
| Ardea Biosciences, Inc. | 72 |
13 |
| UPL Limited | 588 |
11 |
| King Faisal University | 918 |
10 |
| Yuhan Corporation | 227 |
10 |
| The Regents of the University of California | 19961 |
9 |
| FMC Corporation | 845 |
9 |
| The General Hospital Corporation | 4740 |
8 |
| F. Hoffmann-La Roche AG | 7947 |
7 |
| Eli Lilly and Company | 3848 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 165 |
7 |
| The University of Queensland | 661 |
7 |
| Inflazome Limited | 85 |
7 |
| Cv6 Therapeutics (NI) Limited | 32 |
7 |
| Bayer Cropscience AG | 2040 |
6 |
| Sumitomo Chemical Company, Limited | 9043 |
6 |
| Other owners | 413 |